Literature DB >> 6233163

The effects of indalpine--a selective inhibitor of 5-HT uptake--on rat paradoxical sleep.

S Kafi-De St Hilaire, H Merica, J M Gaillard.   

Abstract

In order to document the role of monoamines in the reduction of paradoxical sleep by antidepressant drugs, we examined the effect of indalpine , a selective inhibitor of serotonin uptake. Indalpine dose dependently decreased paradoxical sleep and delayed its first appearance. Pretreatment with parachlorophenylalanine markedly decreased the effect of indalpine . In contrast, pretreatment with alpha-methylparatyrosine potentiated the indalpine -induced depression of paradoxical sleep. The results of the study indicate that the increase of extracellular concentration of 5-HT has an inhibitory effect on paradoxical sleep, and this effect is enlarged if catecholaminergic activity is reduced.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6233163     DOI: 10.1016/0014-2999(84)90290-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

1.  Fluoxetine decreases brain temperature and REM sleep in Syrian hamsters.

Authors:  B Gao; W C Duncan; T A Wehr
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  Similar effect on REM sleep but differential effect on slow wave sleep of the two 5-HT uptake inhibitors zimeldine and alaproclate in cats and rats.

Authors:  L Sommerfelt; E R Hauge; R Ursin
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

3.  Acute administration of the novel serotonin and noradrenaline reuptake inhibitor, S33005, markedly modifies sleep-wake cycle architecture in the rat.

Authors:  Raymond Cespuglio; Colette Rousset; Gabriel Debilly; Catherine Rochat; Mark J Millan
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

4.  Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers.

Authors:  E Mignot; A Renaud; S Nishino; J Arrigoni; C Guilleminault; W C Dement
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

5.  MicroRNA as therapeutic targets for treatment of depression.

Authors:  Katelin F Hansen; Karl Obrietan
Journal:  Neuropsychiatr Dis Treat       Date:  2013-07-29       Impact factor: 2.570

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.